Grace Therapeutics Schedules FDA Meeting for GTx-104 Resubmission, Reports 12-Month Cash Runway
GRCE sits 26% above its 52-week low of $1.79 on light trading volume (0.2× avg).
Summary
Grace Therapeutics announced a scheduled Type A meeting with the FDA to clarify the path for its GTx-104 drug resubmission, alongside reporting a 12-month cash runway and improved fiscal year 2026 financial results.
Key Events · Product Development and Regulatory · GRCE
-
FDA Type A Meeting Scheduled for GTx-104
A Type A meeting has been scheduled with the FDA to clarify the path forward for the GTx-104 NDA resubmission, following the Complete Response Letter (CRL) issued in April 2026. The CRL cited non-clinical and manufacturing issues, with no clinical deficiencies identified.
-
12-Month Cash Runway Confirmed
The company reported $17.0 million in cash and cash equivalents as of March 31, 2026, and believes this is sufficient to sustain planned operations for at least 12 months, addressing immediate liquidity concerns.
-
Improved Fiscal Year 2026 Financials
Grace Therapeutics reported a reduced net loss of $7.8 million, or $0.47 per share, for the fiscal year ended March 31, 2026, an improvement from a $9.6 million net loss ($0.79 per share) in the prior year.
-
New Patent Extends GTx-104 Protection
A new U.S. Patent (No. 12,414,943) was issued, covering the IV dosing regimen for GTx-104 and extending intellectual property protection for the drug to 2043.
Analysis · GRCE · Life Sciences
This filing provides critical updates following the FDA's Complete Response Letter (CRL) for GTx-104 and the recent 10-K filing which included a going concern warning. The scheduled Type A meeting with the FDA offers a concrete path to address the non-clinical issues cited in the CRL, with the company expressing confidence in a resubmission. Crucially, the company's declaration of a 12-month cash runway directly addresses immediate liquidity concerns raised by the going concern warning, providing a temporary reprieve and stability. The improved financial results and new patent further support the company's efforts to navigate its challenges.
How filings like this one have moved
In the 30 days to Nov 2, 2026, 40.4% of the 1069 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GRCE was trading at $2.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $34.4M. The 52-week trading range was $1.79 to $5.18. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.